In the United States,<unk>  is indicated for the treatment of secondary hyperparathyroidism in people with chronic kidney disease on dialysis and hypercalcemia in people with parathyroid carcinoma.<unk>  can also be used to treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. In the European Union<unk>  is indicated for: * the treatment of secondary hyperparathyroidism (HPT) in adults with end stage renal disease (ESRD) on maintenance dialysis therapy. * the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. * part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate. * the treatment of parathyroid carcinoma and primary hyperparathyroidism in adults. * the reduction of hypercalcaemia in adults with: * parathyroid carcinoma; * primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated. Pregnancy and lactation<unk>  has pregnancy category C in the US, meaning that adequate and well-controlled studies involving<unk>  in pregnant women have not been done. Studies have not been done in lactating women; therefore it is not known whether<unk>  is excreted into human milk.
Cinacalcet
Elagolix
Meclizine
Syclix
Naloxegol
Tyramine
Cetirizine
Crofelemer